XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Net revenues $ 3,891 $ 3,819
Cost of sales 2,014 2,048
Gross profit 1,877 1,771
Research and development expenses 247 242
Selling and marketing expenses 622 608
General and administrative expenses 297 278
Intangible assets impairments 121 80
Other assets impairments, restructuring and other items (22) 673
Legal settlements and loss contingencies 86 106
Other loss (income) 5 1
Operating income (loss) 519 (218)
Financial expenses, net 225 250
Income (loss) before income taxes 294 (467)
Income taxes (benefit) 74 (52)
Share in (profits) losses of associated companies, net   4
Net income (loss) 220 (419)
Net income (loss) attributable to redeemable and non-redeemable non-controlling interests 6 (280)
Net income (loss) attributable to Teva $ 214 $ (139)
Earnings (loss) per share attributable to ordinary shareholders:    
Basic $ 0.19 $ (0.12)
Diluted $ 0.18 $ (0.12)
Weighted average number of shares (in millions):    
Basic 1,138 1,123
Diluted 1,159 1,123